Drug Royalty Corp., Massachusetts General Hospital, Alnylam, MIT, BG Medicine, MD Anderson, Case Western | GenomeWeb
Drug Royalty Corp. Buys Future Royalty Rights to Arthritis Drug from MGH
 
Toronto-based Drug Royalty Corporation last week said that it has acquired the future right to receive royalties on the sale of the drug Enbrel from the Massachusetts General Hospital.
 
Under the terms of the agreement, Drug Royalty has paid MGH and Enbrel’s faculty inventors a one-time payment of $300 million less accrued royalties for the period from July 1, 2006 to December 31, 2006.
 

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In Science this week: metagenomic-based technique for determining protein structure, and more.

An academic laments the rise of narcissism in the sciences, the Guardian reports.

Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.

The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.